Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection
详细信息 查看全文
- 作者：Giada V Zapparoli (1)
Robert N Jorissen (2) (3)
Chelsee A Hewitt (1)
Michelle McBean (1)
David A Westerman (1) (4)
Alexander Dobrovic (1) (4) (5) (6) (7) - 关键词：Mutation detection ; Myeloproliferative neoplasms ; Minimal residual disease ; qPCR ; Real time PCR ; JAK2 V617F ; BRAF V600E ; EGFR T790M
- 刊名：BMC Cancer
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：13
- 期：1
- 全文大小：498KB
- 参考文献：1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD: The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. / Blood 2009, 114:937-51. CrossRef
2. Tefferi A: Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. / J Cell Mol Med 2009, 13:215-37. CrossRef
3. James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. / Nature 2005, 434:1144-148. CrossRef
4. Kaushansky K: On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. / Blood 2005, 105:4187-190. CrossRef
5. Pardanani A, Tefferi A: Targeting myeloproliferative neoplasms with JAK inhibitors. / Curr Opin Hematol 2011, 18:105-10. CrossRef
6. Reddy MM, Deshpande A, Sattler M: Targeting JAK2 in the therapy of myeloproliferative neoplasms. / Expert Opin Ther Targets 2012, 16:313-24. CrossRef
7. Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S, Vassiliou G, Bench A, Boyd E, Curtin N: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. / Lancet 2005, 365:1054-061.
8. Er T-K, Lin S-F, Chang J-G, Hsieh L-L, Lin S-K, Wang L-H, Lin C-W, Chang C-S, Liu T-C: Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. / Clin Chim Acta 2009, 408:39-4. CrossRef
9. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP: JAK2 mutation 1849G-gt;?T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. / Blood 2005, 106:3370-373. CrossRef
10. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. / Blood 2005, 106:2162-168. CrossRef
11. Kannim S, Thongnoppakhun W, Auewarakul CU: Two-round allele specific-polymerase chain reaction: a simple and highly sensitive method for JAK2V617F mutation detection. / Clin Chim Acta 2009, 401:148-51. CrossRef
12. Larsen T, Christensen J, Hasselbalch H, Pallisgaard N: The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. / Br J Haematol 2007, 136:745-51. CrossRef
13. Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B, Boggon T, Wlodarska I, Clark J, Moore S: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. / Cancer Cell 2005, 7:387-97. CrossRef
14. Poodt J, Fijnheer R, Walsh IBB, Hermans MHA: A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. / Hematol Oncol 2006, 24:227-33. CrossRef
15. Qian J, Lin J, Yao D-M, Chen Q, Xiao G-F, Ji R-B, Li Y, Yang J, Qian Z: Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. / Clin Chim Acta 2010, 411:2097-100. CrossRef
16. Sutton BC, Allen RA, Zhao ZJ, Dunn ST: Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. / Cancer Biomark 2007, 3:315-24.
17. Tan AYC, Westerman DA, Dobrovic A: A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. / Am J Clin Pathol 2007, 127:977-81. CrossRef
18. Ugo V, Tondeur S, Menot ML, Bonnin N, Le Gac G, Tonetti C, Mansat-De Mas V, Lecucq L, Kiladjian JJ, Chomienne C: Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. / PLoS One 2010, 5:e8893. CrossRef
19. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, Fu X, Zhao ZJ: JAK2(V617F): Prevalence in a large Chinese hospital population. / Blood 2007, 109:339-42. CrossRef
20. Zhao AH, Gao R, Zhao ZJ: Development of a highly sensitive method for detection of JAK2V617F. / J Hematol Oncol 2011, 4:40. CrossRef
21. Cankovic M, Whiteley L, Hawley RC, Zarbo RJ, Chitale D: Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory. / Am J Clin Pathol 2009, 132:713-21. CrossRef
22. Denys B, El Housni H, Nollet F, Verhasselt B, Philippe J: A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide. / J Mol Diagn 2010, 12:512-19. CrossRef
23. Hammond E, Shaw K, Carnley B, P’ng S, James I, Herrmann R: Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. / J Mol Diagn 2007, 9:242-48. CrossRef
24. Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M, Reiter A, Zabelina T, Zander AR, Fehse B: Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. / Blood 2007, 109:1316-321. CrossRef
25. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupre N, Skoda RC, Hermouet S: The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. / Blood 2006, 108:1865-867. CrossRef
26. Sidon P, Heimann P, Lambert F, Dessars B, Robin V, El Housni H: Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant. / Clin Chem 2006, 52:1436-438. CrossRef
27. Siebolts U, Lange T, Niederwieser D, Wickenhauser C: Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy. / J Clin Pathol 2010, 63:370-72. CrossRef
28. Bench AJ, White HE, Foroni L, Godfrey AL, Gerrard G, Akiki S, Awan A, Carter I, Goday-Fernandez A, Langabeer SE: Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. / Br J Haematol 2013, 160:25-4. CrossRef
29. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ, Moorman AF: Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. / Nucleic Acids Res 2009, 37:e45. CrossRef
30. Tuomi JM, Voorbraak F, Jones DL, Ruijter JM: Bias in the Cq value observed with hydrolysis probe based quantitative PCR can be corrected with the estimated PCR efficiency value. / Methods 2010, 50:313-22. CrossRef
31. R Development Core Team: / R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria; 2011. ISBN 3-00051-7-, URL http://www.R-project.org/
32. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S: Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. / Haematologica 2009, 94:38-5. CrossRef
33. Okayama H, Curiel DT, Brantly ML, Holmes MD, Crystal RG: Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification. / J Lab Clin Med 1989, 114:105-13.
34. Seyama T, Ito T, Hayashi T, Mizuno T, Nakamura N, Akiyama M: A novel blocker-PCR method for detection of rare mutant alleles in the presence of an excess amount of normal DNA. / Nucleic Acids Res 1992, 20:2493-496. CrossRef
35. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF: Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). / Nucleic Acids Res 1989, 17:2503-516. CrossRef
36. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. / Proc Natl Acad Sci U S A 1977, 74:5463-467. CrossRef
37. Orou A, Fechner B, Utermann G, Menzel HJ: Allele-specific competitive blocker PCR: a one-step method with applicability to pool screening. / Hum Mutat 1995, 6:163-69. CrossRef
38. Gudnason H, Dufva M, Bang DD, Wolff A: Comparison of multiple DNA dyes for real-time PCR: effects of dye concentration and sequence composition on DNA amplification and melting temperature. / Nucleic Acids Res 2007, 35:e127. CrossRef
39. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/206/prepub - 作者单位：Giada V Zapparoli (1)
Robert N Jorissen (2) (3)
Chelsee A Hewitt (1)
Michelle McBean (1)
David A Westerman (1) (4)
Alexander Dobrovic (1) (4) (5) (6) (7)
1. Department of Pathology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, 3002, Australia
2. Walter and Eliza Hall Institute of Medical Research, Parkville, 3052, Australia
3. Department of Medical Biology, University of Melbourne, Parkville, Australia
4. Division of Cancer Medicine, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, 3002, Australia
5. Department of Pathology, University of Melbourne, Parkville, Victoria, 3010, Australia
6. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, 3010, Australia
7. Molecular Pathology Research & Development, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, 3002, Australia - ISSN：1471-2407
文摘
Background The JAK2 V617F mutation is the most frequent somatic change in myeloproliferative neoplasms, making it an important tumour-specific marker for diagnostic purposes and for the detection of minimal residual disease. Sensitive quantitative assays are required for both applications, particularly for the monitoring of minimal residual disease, which requires not only high sensitivity but also very high specificity. Methods We developed a highly sensitive probe-free quantitative mutant-allele detection method, Quantitative Threefold Allele-Specific PCR (QuanTAS-PCR), that is performed in a closed-tube system, thus eliminating the manipulation of PCR products. QuantTAS-PCR uses a threefold approach to ensure allele-specific amplification of the mutant sequence: (i) a mutant allele-specific primer, (ii) a 3′dideoxy blocker to suppress false-positive amplification from the wild-type template and (iii) a PCR specificity enhancer, also to suppress false-positive amplification from the wild-type template. Mutant alleles were quantified relative to exon 9 of JAK2. Results We showed that the addition of the 3′dideoxy blocker suppressed but did not eliminate false-positive amplification from the wild-type template. However, the addition of the PCR specificity enhancer near eliminated false-positive amplification from the wild-type allele. Further discrimination between true and false positives was enabled by using the quantification cycle (Cq) value of a single mutant template as a cut-off point, thus enabling robust distinction between true and false positives. As 10,000 JAK2 templates were used per replicate, the assay had a sensitivity of 1/10-4 per replicate. Greater sensitivity could be reached by increasing the number of replicates analysed. Variation in replicates when low mutant-allele templates were present necessitated the use of a statistics-based approach to estimate the load of mutant JAK2 copies. QuanTAS-PCR showed comparable quantitative results when validated against a commercial assay. Conclusions QuanTAS-PCR is a simple, cost-efficient, closed-tube method for JAK2 V617F mutation quantification that can detect very low levels of the mutant allele, thus enabling analysis of minimal residual disease. The approach can be extended to the detection of other recurrent single nucleotide somatic changes in cancer.